Tashatuvango / shutterstock.com

18 April 2017Americas

UC, Berkeley appeals to Federal Circuit in CRISPR patent clash

The University of California (UC), Berkeley and the University of Vienna have appealed against the Patent Trial and Appeal Board's (PTAB) decision in the dispute over CRISPR technology.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

PTAB says Broad's CRISPR patents do not interfere with UC Berkeley's

16 February 2017 The Broad Institute of Harvard and MIT’s patents concerning CRISPR technology do not interfere with patent claims filed by the University of California, Berkeley and the University of Vienna.

Broad Institute takes three lines of attack in CRISPR appeal filing

26 October 2017 The Broad Institute of Harvard and MIT has adopted three major arguments in its response to the University of California, Berkeley’s appeal against a patent finding on the CRISPR technology.

More on this story

PTAB says Broad's CRISPR patents do not interfere with UC Berkeley's

16 February 2017 The Broad Institute of Harvard and MIT’s patents concerning CRISPR technology do not interfere with patent claims filed by the University of California, Berkeley and the University of Vienna.

Broad Institute takes three lines of attack in CRISPR appeal filing

26 October 2017 The Broad Institute of Harvard and MIT has adopted three major arguments in its response to the University of California, Berkeley’s appeal against a patent finding on the CRISPR technology.

More on this story

PTAB says Broad's CRISPR patents do not interfere with UC Berkeley's

16 February 2017 The Broad Institute of Harvard and MIT’s patents concerning CRISPR technology do not interfere with patent claims filed by the University of California, Berkeley and the University of Vienna.

Broad Institute takes three lines of attack in CRISPR appeal filing

26 October 2017 The Broad Institute of Harvard and MIT has adopted three major arguments in its response to the University of California, Berkeley’s appeal against a patent finding on the CRISPR technology.

More features

Gilead scores win in fake HIV drug dispute

Polsinelli grows roster with ex-corporate counsel

‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird

Sandoz wins $137.2m payout for lost profits in generic launch

Sanofi signs global rights deal to develop rare cancer therapy

Unified Patent Court visualised: Cases, divisions, and classes in charts

WBD to merge with firm to create ‘powerhouse’ practice

‘Be prepared, and don’t assume at the UPC’: Christopher Stothers